Cilostazol

A summary of the most common chemical descriptors (InChI Key and SMILES codes) for Cilostazol are summarized together with 3D and 2D structures and relevant physico-chemical properties.

What is the Cilostazol?

The molecule Cilostazol presents a molecular formula of C35H35F2N8O5S+ and its IUPAC name is 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one.

Cilostazol is a quinolinone derivative that inhibits phosphodiesterase 3 (PDE3) and thus prevents degradation of cyclic adenosine monophosphate (cAMP) in platelets. It also has some direct vasodilatory properties. Cilostazol is used to treat intermittent claudication, which results from obstruction of blood flow in arteries..

Cilostazol was developed by Mitsubishi Pharma in Japan and is marketed under the brand name Pletal. It exists as a generic drug in the United States..

The most common side effects of cilostazol are headache, diarrhea, and abdominal pain. Cilostazol can also cause dizziness and lightheadedness. These side effects are usually mild and resolve with time..

Cilostazol is contraindicated in people with heart failure, uncontrolled hypertension, or a history of stroke. It should be used with caution in people with kidney or liver impairment..

Cilostazol has been shown to be effective in reducing the symptoms of intermittent claudication and improving quality of life. It is a safe and well-tolerated medication with a low risk of serious side effects..

3D structure

Cartesian coordinates

Geometry of Cilostazol in x, y and z coordinates (Å units) to copy/paste elsewhere. Generated with Open Babel software.

2D drawing

 

Cilostazol RSWOJTICKMKTER-GEJZGCERSA-N chemical compound 2D structure molecule svg
Cilostazol

 

Molecule descriptors

 
IUPAC name6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
InChI codeInChI=1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23+,35+/m0/s1
InChI KeyRSWOJTICKMKTER-GEJZGCERSA-N
SMILESCNCC(=O)OCc1cccnc1N(C)C(=O)O[C@H](C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1

Other names (synonyms)

IUPAC nomenclature provides a standardized method for naming chemical compounds. Although this system is widely used in chemistry, many chemical compounds have also other names commonly used in different contexts. These synonyms can come from a variety of sources and are used for a variety of purposes.

One common source of synonyms for chemical compounds is the common or trivial names, assigned on the basis of appearance, properties, or origin of the molecule.

Another source of synonyms are historical or obsolete names employed in the past, however replaced nowadays by more modern or standardized names.

In addition to common and historical names, chemical compounds may also have synonyms that are specific to a particular field or industry.

  • 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-
  • 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-
  • 2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-
  • 2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-
  • 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
  • 6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)QUINOLINE-2,3(1H,4H)-DIONE
  • 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
  • 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
  • 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
  • 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
  • 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
  • 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
  • 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one
  • 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
  • 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
  • 6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril
  • 73963-72-1
  • 89332-50-3
  • 963C721
  • A837982
  • AB00382988-14
  • AB00382988_15
  • AB00382988_16
  • AC-4334
  • ACT02663
  • AM90304
  • BCP03724
  • BCP0726000145
  • BCP9000530
  • BCPP000279
  • BDBM50225508
  • BRN 3632107
  • BSPBio_002759
  • C 0737
  • CCG-39646
  • CS-1759
  • Cilastatin sodium, Antibiotic for Culture Media Use Only
  • Cilostazol
  • Cilostazol (JP17/USP/INN)
  • Cilostazol,(S)
  • Cilostazol-[d11]
  • Cilostazole
  • Cilostazolum
  • D01896
  • DB01166
  • DSSTox_CID_25132
  • DSSTox_GSID_45132
  • DSSTox_RID_80693
  • EU-0100218
  • F20538
  • FT-0602474
  • FT-0645036
  • FT-0665038
  • GTPL7148
  • HMS1922N15
  • HMS2093M14
  • HMS2096F16
  • HMS2234C06
  • HMS3260L17
  • HMS3268O09
  • HMS3412B18
  • HMS3654J13
  • HMS3676B18
  • HMS3713F16
  • HSDB 8312
  • HY-17464
  • KBio3_002259
  • KBioGR_001184
  • KS-5154
  • LP00218
  • Lopac-C-0737
  • Lopac0_000218
  • MFCD00866780
  • MLS000028470
  • MLS000758281
  • MLS000759507
  • MLS001076067
  • MLS002153891
  • N7Z035406B
  • NCGC00015207-01
  • NCGC00015207-02
  • NCGC00015207-03
  • NCGC00015207-04
  • NCGC00015207-05
  • NCGC00015207-06
  • NCGC00015207-07
  • NCGC00015207-08
  • NCGC00015207-09
  • NCGC00015207-10
  • NCGC00015207-11
  • NCGC00015207-12
  • NCGC00015207-25
  • NCGC00022153-02
  • NCGC00022153-04
  • NCGC00022153-05
  • NCGC00022153-06
  • NCGC00022153-07
  • NCGC00260903-01
  • NSC 758936
  • NSC-758936
  • NSC758936
  • OPC 13013
  • OPC 13013; OPC 21; Pletaal
  • OPC 21
  • OPC-13013
  • OPC-21
  • Opera_ID_488
  • Pharmakon1600-01505230
  • Pletaal
  • Pletal
  • Q-200854
  • Q258591
  • REGID_for_CID_2754
  • RETAL;PLETAL;OPC 21;PLETAAL;Cilostal
  • SBI-0050206.P002
  • SDCCGSBI-0050206.P003
  • SMR000058428
  • SPECTRUM1505230
  • SR-01000003107
  • SR-01000003107-10
  • SR-01000003107-2
  • SR-01000003107-4
  • SR-01000003107-7
  • SW199053-2
  • Tocris-1692
  • cilostazol
  • s1294

Reference codes for other databases

There exist several different chemical codes commonly used in orded to identify molecules:
  • ZINC1552174
  • CAS-73963-72-1
  • UNII-N7Z035406B
  • AKOS015855512
  • BRD-K67017579-001-04-2
  • BRD-K67017579-001-05-9
  • BRD-K67017579-001-07-5
  • BRD-K67017579-001-13-3
  • BRD-K67017579-001-17-4
  • DTXSID9045132
  • CHEMBL799
  • CHEBI:31401
  • Tox21_110098
  • Tox21_500218
  • Tox21_110098_1
  • SPBio_001256
  • SCHEMBL16128
  • Spectrum2_001118
  • Spectrum3_001170
  • Spectrum4_000772
  • Spectrum5_001762

Physico-Chemical properties

IUPAC name6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
Molecular formulaC35H35F2N8O5S+
Molecular weight717.765
Melting point (ºC)
Boiling point (ºC)
Density (g/cm3)
Molar refractivity183.54
LogP5.0
Topological polar surface area187.6

LogP and topological polar surface area (TPSA) values were estimated using Open Babel software.

The n-octanol/water partition coeficient (Kow) data is applied in toxicology and drug research. Kow values are used, to guess the environmental fate of persistent organic pollutants. High partition coefficients values, tend to accumulate in the fatty tissue of organisms. Molecules with a log(Kow) (or LogP) greater than 5 are considered to bioaccumulate.

TPSA values are the sum of the surface area over all polar atoms or molecules, mainly oxygen and nitrogen, also including hydrogen atoms.

In medicinal chemistry, TPSA is used to assess the ability of a drug to permeabilise cells.

For molecules to penetrate the blood-brain barrier (and act on receptors in the central nervous system), TPSA values below 90 Å2 are required. Thus, molecules with a polar surface area greater than 140 Å2 tend to be poorly permeable to cell membranes.